ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

teclistamab

Also written as “Teclistamab”, “Teclistamab (IV)” and “Teclistamab(SC)”.

Its studies are mostly in Multiple Myeloma · Hematologic Neoplasms, led by Johnson & Johnson.

Drug pageTeclistamab: every studyAll 45 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 12, 202511 company-led studies, 10 open or runningNext primary completion: Feb 12, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson1110 open or runningphase 4since Jun 12, 2025Apr 28, 2017Feb 12, 2027phase 4 · NCT07030517

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Apr 28, 2017First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT03145181 · 302 enrolled · United States, France, Netherlands and more
  2. Dec 9, 2018Named teclistamabINNProposed as its International Nonproprietary Name in WHO's List 120
  3. Sep 17, 2020Phase 2 study in Hematologic NeoplasmsNCT04557098 · 194 enrolled · United States, Belgium, Canada and more
  4. Oct 12, 2020Phase 2 study in Multiple MyelomaNCT04586426 · 228 enrolled · United States, Australia, Canada and more
  5. Jan 5, 2021Phase 2 study in Hematologic NeoplasmsNCT04696809 · 40 enrolled · Japan
  6. Oct 8, 2021Phase 3 study in Multiple MyelomaNCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
  7. Mar 31, 2022Phase 1 study in Relapsed/ Refractory Multiple MyelomaNCT05338775 · 74 enrolled · United States, France, Germany and more
  8. Sep 21, 2022Phase 3 study in Multiple MyelomaNCT05552222 · 1,590 planned · United States, Australia, Austria and more
  9. Oct 5, 2022Phase 3 study in Multiple MyelomaNCT05572515 · 614 enrolled · United States, Australia, Austria and more
  10. Jan 5, 2024Phase 3 study in Multiple MyelomaNCT06208150 · 838 enrolled · United States, Argentina, Australia and more
  11. May 17, 2024Phase 1 study in Multiple MyelomaNCT06425991 · 108 enrolled · United States, Australia, Canada and more
  12. Jun 12, 2025Phase 4 study in Multiple MyelomaNCT07030517 · 75 enrolled · India
  13. Nov 3, 2026Primary completion moved from 2026-11-03 to 2027-02-12Date moved laterphase 4 · +3 months · NCT07030517

Ahead

  1. Feb 12, 2027Primary completion: phase 4 study in Multiple MyelomaNCT07030517
  2. Apr 30, 2031Primary completion: phase 3 study in Multiple MyelomaNCT05552222

TargetBeta

“A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human B-cell maturation antigen (BCMA; TNFRSF17), a tumor-associated antigen (TAA) expressed on plasma cells, ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Tumor necrosis factor receptor superfamily member 17 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rulekelonia-therapeutics-incphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07030517Multiple Myeloma · India4Active, not recruitingFeb 12, 202775
NCT06425991Multiple Myeloma · United States, Australia, Canada and more1Active, not recruitingApr 21, 2025108
NCT06208150Multiple Myeloma · United States, Argentina, Australia and more3Active, not recruitingApr 1, 2026838
NCT05572515Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingOct 13, 2025614
NCT05552222Multiple Myeloma · United States, Australia, Austria and more3RecruitingApr 30, 20311,590
NCT05338775Relapsed/ Refractory Multiple Myeloma · United States, France, Germany and more1Active, not recruitingMay 22, 202574
NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more3Active, not recruitingAug 1, 2025587
NCT04696809Hematologic Neoplasms · Japan2CompletedApr 13, 202640
NCT04586426Multiple Myeloma · United States, Australia, Canada and more2Active, not recruitingMar 18, 2025228
NCT04557098Hematologic Neoplasms · United States, Belgium, Canada and more2Active, not recruitingNov 9, 2021194
NCT03145181Hematologic Neoplasms · United States, France, Netherlands and more1Active, not recruitingSep 25, 2025302

How it is read

Names in the registry

  • “Teclistamab”, 10 entries
  • “Teclistamab (IV)”, 1 entry
  • “Teclistamab(SC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.